Barclays Maintains Overweight on Vontier, Lowers Price Target to $33
Barclays analyst Julian Mitchell maintains Vontier (NYSE:VNT) with a Overweight and lowers the price target from $39 to $33.
Barclays Maintains Overweight on Delta Air Lines, Lowers Price Target to $45
Barclays analyst Brandon Oglenski maintains Delta Air Lines (NYSE:DAL) with a Overweight and lowers the price target from $60 to $45.
Barclays Maintains Equal-Weight on United Airlines Holdings, Lowers Price Target to $45
Barclays analyst Brandon Oglenski maintains United Airlines Holdings (NASDAQ:UAL) with a Equal-Weight and lowers the price target from $58 to $45.
UBS Downgrades Illinois Tool Works to Neutral, Lowers Price Target to $185
UBS analyst Steven Fisher downgrades Illinois Tool Works (NYSE:ITW) from Buy to Neutral and lowers the price target from $243 to $185.
UBS Downgrades Kennametal to Sell, Lowers Price Target to $19
UBS analyst Steven Fisher downgrades Kennametal (NYSE:KMT) from Neutral to Sell and lowers the price target from $27 to $19.
JMP Securities Downgrades Upstart Hldgs to Market Perform
JMP Securities analyst Andrew Boone downgrades Upstart Hldgs (NASDAQ:UPST) from Market Outperform to Market Perform.
Wells Fargo Downgrades iHeartMedia to Equal-Weight, Lowers Price Target to $9
Wells Fargo analyst Steven Cahall downgrades iHeartMedia (NASDAQ:IHRT) from Overweight to Equal-Weight and lowers the price target from $23 to $9.
Wells Fargo Upgrades Interpublic Gr of Cos to Overweight, Lowers Price Target to $33
Wells Fargo analyst Steven Cahall upgrades Interpublic Gr of Cos (NYSE:IPG) from Equal-Weight to Overweight and lowers the price target from $40 to $33.
Benchmark Initiates Coverage On DPCM Capital with Buy Rating, Announces Price Target of $14
Benchmark analyst David Williams initiates coverage on DPCM Capital (NYSE:XPOA) with a Buy rating and announces Price Target of $14.
Chardan Capital Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $18
Chardan Capital analyst Geulah Livshits initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $18.